{"id":"NCT02561078","sponsor":"Eli Lilly and Company","briefTitle":"An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus","officialTitle":"Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-20","primaryCompletion":"2017-05-09","completion":"2017-05-09","firstPosted":"2015-09-25","resultsPosted":"2020-05-20","lastUpdate":"2020-05-20"},"enrollment":420,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Human regular U-500 insulin (CSII)","otherNames":["LY041001"]},{"type":"DRUG","name":"Human regular U-500 insulin (MDI)","otherNames":["LY041001"]}],"arms":[{"label":"Human regular U-500 insulin administered by CSII","type":"EXPERIMENTAL"},{"label":"Human regular U-500 insulin administered by MDI","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, 26 Weeks","effectByArm":[{"arm":"Human Regular U-500 Insulin Administered by CSII","deltaMin":-1.27,"sd":0.072},{"arm":"Human Regular U-500 Insulin Administered by MDI","deltaMin":-0.85,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":57,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/adult-type-2-diabetes/IBHD#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":209},"commonTop":["Upper respiratory tract infection","Diarrhoea","Viral upper respiratory tract infection","Weight increased","Nausea"]}}